Life Science News

Medtronic PulseSelect PFA System demonstrates impressive results in landmark PULSED AF global IDE trial

ACC.23/WCC late-breaking data: PULSED AF, one of the most rigorously executed PFA clinical studies to date, exceeds safety and efficacy performance goals in the treatment of paroxysmal and persistent atrial fibrillation

- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that its PulseSelect™ Pulsed Field Ablation (PFA) System exceeded its safety performance goal, with an adverse event rate of 0.7%, one of the lowest adverse event rates of any prior U.S. FDA Investigational Device Exemption (IDE) trial for atrial fibrillation (AF) ablation or any multi-center PFA study. PULSED AF exceeded the threshold for its efficacy performance goal and further, clinical success, freedom from recurrence of any symptomatic atrial arrhythmias, was at least 80% for each patient cohort. Findings from the PULSED AF Pivotal Trial were presented as a late-breaking trial today at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.23WCC) and simultaneously published in Circulation.

Medtronic PulseSelect PFA System demonstrates impressive results in landmark PULSED AF global IDE trial

PULSED AF is the first and only completed, global, and multi-center clinical study with IDE approval to evaluate the safety and effectiveness of PFA technology for AF ablation. PFA is a breakthrough ablation technology that uses pulsed electric fields to efficiently isolate the pulmonary veins for the treatment of patients with paroxysmal or persistent AF.

PULSED AF is designed to evaluate the safety and efficacy of the PulseSelect System for the treatment of AF in adult patients with a history of drug refractory, recurrent and symptomatic paroxysmal or persistent AF. The trial is a prospective, single arm, multi-center clinical trial that treated 300 patients (150 with paroxysmal AF and 150 with persistent AF). Patients were enrolled across 41 sites in nine countries with 67 operators throughout the United States , Canada , Europe , Australia , and Japan .

Study Results: Safety
The study exceeded its performance goal of freedom from a composite of serious procedure and device-related adverse events with a 0.7% (p=0.002) rate of primary adverse events in both patient cohorts. There were no esophageal events, instances of pulmonary vein stenosis, or phrenic nerve injury.

"Uniquely, these results represent the first prospective, global, large-scale study with two different, rigorously monitored patient populations that demonstrates an impressively low adverse event rate of 0.7%," said Atul Verma , M.D., electrophysiologist and director, Division of Cardiology, McGill University Health Centre in Montreal and principal investigator (PI) for the PULSED AF study. "The results of PFA trials have been highly anticipated among the EP community to help us treat the growing number of AF patients around the world. The high rate of 80% or more in clinical success and the promising safety and efficiency results from PULSED AF will help establish PFA as an exciting new option for patients."

Study Results: Efficacy
PULSED AF exceeded the threshold for efficacy performance at 66% efficacy in paroxysmal AF patients and 55% in persistent AF patients (p50% (paroxysmal) and >40% (persistent) at 12 months. The PULSED AF primary effectiveness endpoint included a composite of measures based on efficacy endpoints across multiple studies of radiofrequency (RF) and cryoablation energy sources. The composite endpoint included freedom from acute procedural failure, arrhythmia recurrence, repeat ablation, direct current cardioversion, left atrial surgery, or antiarrhythmic escalation through twelve months, excluding a 3-month blanking period.

Freedom from atrial arrhythmia recurrence at 12 months was 70% in the paroxysmal cohort and 62% in the persistent. Additionally, clinical success, freedom from recurrence of any symptomatic atrial arrhythmias, was 80% for paroxysmal and 81% for the persistent cohort.

"Today's findings demonstrate a critical achievement in the decade-long commitment we have made to researching PFA and underscores our confidence in the PulseSelect System," said Rebecca Seidel , president, Cardiac Ablation Solutions business, which is part of the Cardiovascular Portfolio at Medtronic. "We are taking the same comprehensive approach to PFA that we took with the introduction of the single-shot Arctic Front Advance™ cryoballoon, and that involves building a deep, extensive  body of clinical evidence and strong collaboration with clinicians globally. The single-shot PulseSelect System, together with the focal Affera Sphere-9™ mapping and ablation catheter, will allow us to offer a complementary suite of PFA technologies to help treat patients with AF and other arrhythmias."

About Patient Monitoring Strategies
Published PFA studies utilize different monitoring frequency and endpoints. For PULSED AF, patients underwent rigorous arrhythmia monitoring with assessments at three, six, and 12 months, and weekly symptomatic trans-telephonic monitoring. 96% (287) of patients completed the 12-month follow up. PFA study results cannot be directly compared; however, to show the impact of how monitoring differences affect outcome measurements, Medtronic analyzed its own data using the monitoring frequency and endpoints used in other PFA studies 9 and found the PULSED AF outcomes to be higher when using those metrics.

The single-shot PulseSelect System delivers pulsed electric fields through an ablation catheter designed specifically to interrupt irregular electrical pathways in the heart that trigger AF. However, unlike traditional methods of ablation that heat (radiofrequency ablation) or cool (cryoablation) the atrial tissue, the PulseSelect System uses a non-thermal approach and preferentially targets heart tissue with the goal of avoiding unwanted injury to surrounding structures, a risk of current ablation technologies. Worldwide, the PulseSelect System is investigational and not approved for sale or distribution. For more information on PULSED AF, visit Medtronic.com/PFA.

AF is one of the most common and undertreated heart rhythm disorders, affecting more than 60 million people worldwide. 1 AF is a progressive disease meaning it can become worse over time and can increase the risk of serious complications including heart failure, stroke and increased risk of death 2-5 . Antiarrhythmic drug (AAD) therapy has been the current standard first-line treatment, however, AAD therapy is ineffective at controlling AF in approximately half of patients treated with drug therapy. 6-8

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn.

  1. Roth GA, Mensah GA, Johnson CO et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol 2020;76:2982-3021.
  2. Miyasaka Y, Barnes ME, Bailey KR, et al. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol 2007;49:986-92.
  3. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020.
  4. Wolf PA , Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
  5. Lubitz SA, Moser C, Sullivan L, et al. Atrial fibrillation patterns and risks of subsequent stroke, heart failure, or death in the community. J Am Heart Assoc 2013;2:e000126
  6. Wazni OM, Dandamudi G, Sood N, et al. Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation. N Engl J Med. January 28, 2021;384(4):316-324.
  7. Kuniss M, Pavlovic N, Velagic V, et al. Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation. Europace. March 17, 2021:euab029.
  8. Andrade JG, Wells GA, Deyell MW, et al. Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. N Engl J Med. January 28, 2021;384(4):305-315.
  9. Medtronic data on file March 2023 . Post-hoc Medtronic analysis efficacy of 70.9% and 91.3% for the paroxysmal cohort using inspIRE and MANIFEST monitoring protocol and endpoints, respectively, and 86.3% in the persistent cohort using the MANIFEST monitoring protocol and endpoints. The analysis is based on publicly available published or presented monitoring methods from Biosense Webster inspIRE and Boston Scientific FARAPULSE MANIFEST-PF Survey. These outcome rates should not be used to compare the Pulsed AF results to other trial results, as the results have not been adjusted for patient characteristics.

Contacts:




Allison Kyriagis

Ryan Weispfenning

Public Relations

Investor Relations

+1-612-750-6061

+1-763-505-4626

(PRNewsfoto/Medtronic plc)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-pulseselect-pfa-system-demonstrates-impressive-results-in-landmark-pulsed-af-global-ide-trial-301763305.html

SOURCE Medtronic plc

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2023/06/c0952.html

News Provided by Canada Newswire via QuoteMedia

MDT
The Conversation (0)
Energy Fuels Announces Q2-2022 Results, Including Continued Robust Balance Sheet and Market-Leading U.S. Uranium & Rare Earth Positions

Energy Fuels Announces Q2-2022 Results, Including Continued Robust Balance Sheet and Market-Leading U.S. Uranium & Rare Earth Positions

Webcast on August 9, 2022

Energy Fuels Inc. (NYSE: UUUU) (TSX: EFR) ("Energy Fuels" or the "Company") today reported its financial results for the quarter ended June 30, 2022 . The Company's quarterly report on Form 10-Q has been filed with the U.S. Securities and Exchange Commission (" SEC ") and may be viewed on the Electronic Document Gathering and Retrieval System (" EDGAR ") at www.sec.govedgar.shtml on the System for Electronic Document Analysis and Retrieval (" SEDAR ") at www.sedar.com and on the Company's website at www.energyfuels.com . Unless noted otherwise, all dollar amounts are in U.S. dollars.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Energy Fuels Announces Q1-2022 Results, Including Continued Robust Balance Sheet, Market-Leading U.S. Uranium Position & Rare Earth Production

Energy Fuels Announces Q1-2022 Results, Including Continued Robust Balance Sheet, Market-Leading U.S. Uranium Position & Rare Earth Production

Webcast on May 18, 2022

Energy Fuels Inc. (NYSE: UUUU) (TSX: EFR) ("Energy Fuels" or the "Company") today reported its financial results for the quarter ended March 31, 2022 . The Company's annual report on Form 10-K has been filed with the U.S. Securities and Exchange Commission (" SEC ") and may be viewed on the Electronic Document Gathering and Retrieval System (" EDGAR ") at www.sec.govedgar.shtml on the System for Electronic Document Analysis and Retrieval (" SEDAR ") at www.sedar.com and on the Company's website at www.energyfuels.com . Unless noted otherwise, all dollar amounts are in U.S. dollars.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Energy Fuels Announces 2021 Results, Including Net Profits, Strong Cash Position, and Market-Leading U.S. Uranium, Rare Earth and Vanadium Position

Energy Fuels Announces 2021 Results, Including Net Profits, Strong Cash Position, and Market-Leading U.S. Uranium, Rare Earth and Vanadium Position

Webcast on March 17, 2022

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) ("Energy Fuels" or the "Company") today reported its financial results for the year ended December 31, 2021 . The Company's annual report on Form 10-K has been filed with the U.S. Securities and Exchange Commission (" SEC ") and may be viewed on the Electronic Document Gathering and Retrieval System (" EDGAR ") at www.sec.govedgar.shtml on the System for Electronic Document Analysis and Retrieval (" SEDAR ") at www.sedar.com and on the Company's website at www.energyfuels.com . Unless noted otherwise, all dollar amounts are in U.S. dollars.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Cloud DX's Post-Surgical Monitoring Wearable Validated in Peer-Reviewed Study

Cloud DX's Post-Surgical Monitoring Wearable Validated in Peer-Reviewed Study

Cloud DX's Post-Surgical Monitoring Wearable Validated in Peer-reviewed Study For the ~800,000 1 Canadian surgery patients per year, continuous monitoring with Vitaliti™ could enable earlier intervention in cases of patient decline.

  • Validation of Cloud DX's Vitaliti™ continuous monitoring device clears way for regulatory approval starting in 2022.
  • Accurate continuous data collection supports earlier detection of changes in patient condition, enabling rapid interventions to improve patient outcomes.
  • Clear opportunity to impact up to ~800,000 1 surgical patients per year in Canada, deliverable through recent partnership with medical technology leader Medtronic.

Cloud DX (TSXV:CDX)(OTCQB:CDXFF), Leading Virtual Care Platform Cloud DX has announced publication of an independent peer-reviewed validation study of its unique Vitaliti™ product, a non-invasive wearable devices that provides continuous vital sign monitoring (CVSM) device. The study assessed regulatory compliance and post-surgery use in monitoring patients' vital signs in real-world conditions. The study found Vitaliti™ to be fully ISO 81060-2:2018 compliant for the continuous vital measurement, clearing the way for regulatory approval starting in 2022. The study also found that patients welcomed the comfortable, easy to use device. Instead of care teams taking vitals periodically after surgery, Cloud DX's Vitaliti™ was used for continuous monitoring, which could transform post-surgical care by enabling early detection if any deterioration occurs in patient health. On launch, Vitaliti™ will become a key component of Cloud DX's Connected Health™ ecosystem of remote monitoring technologies. Through Cloud DX's recent partnership with Medtronic Canada ULC (a subsidiary of Medtronic plc (MDT), a global leader in healthcare technology), wide deployment of Vitaliti™ is intended to initially improve post-operative care for surgical patients in Canada (up to 800,000 annually) and eventually in the United States (up to several million annually

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
InvestmentPitch Media Video Discusses Cloud DX's Selection by Medtronic for Canada-Wide Remote Patient Monitoring - Video Available on Investmentpitch.com

InvestmentPitch Media Video Discusses Cloud DX's Selection by Medtronic for Canada-Wide Remote Patient Monitoring - Video Available on Investmentpitch.com

Cloud DX Inc. (TSXV: CDX) (OTCQB: CDXFF) has been selected by Medtronic Canada ULC, to provide world-class virtual healthcare to Medtronic's patients across Canada. Medtronic Canada, (www.medtronic.ca) headquartered in Brampton, Ontario, with regional offices in Montreal and Vancouver, is the largest medical technology company in Canada, and a subsidiary of Medtronic plc (NYSE: MDT), a multi billion-dollar, global leader in medical technology, offering medical devices and therapies to more than 72 million people across 150 countries.

For more information, please view the InvestmentPitch Media "video" which provides additional information about this news and the company, along with comments from Robert Kaul, CEO of Cloud DX, about the significance of this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter "Cloud DX" in the search box.

This partnership advances Medtronic's commitment to improving patient outcomes and lowering overall costs along the care continuum. Medtronic Canada delivers care in a broad range of clinical areas, including spinal and cardiac surgeries, cardiology, critical care, diabetes, vascular and renal care. Most clinical areas are expected to improve patient outcomes and satisfaction with some aspect of virtual care in the future.

Cloud DX's Connected Health™ remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable aging in place, and deliver hospital-quality post-surgical care in the home. Its partners achieve better healthcare and patient outcomes, reduce the need for hospitalization or re-admission, and reduce healthcare delivery costs through more efficient use of resources.

Cloud DX's remote patient monitoring technology and services are exclusive to Medtronic and its Canada-wide client base. Initially, Medtronic seeks to integrate the Connected Health™ platform and associated services within both perioperative and complex chronic disease pathways in Canada.

Under the agreement, a typical deployment would involve the enrollment of a chronic care or surgical patient onto the Connected Health™ platform, generating recurring revenue, depending on the length of the monitoring program. Cloud DX generates revenue upfront for kits prescribed to patients for use at home, and then a monthly subscription fee per patient for software, services, and support. Additional revenues could also be generated through customizations, consulting, and special services, as needed.

Jessica Rudd, National Director of New Partnerships and Solutions at Medtronic Canada, stated: "Medtronic is committed to partnering with Canada-based SMEs to advance the Canadian life sciences ecosystem. More importantly, Medtronic Canada is dedicated to responding to the needs of our Canadian healthcare system, and we are committed to enabling equitable access to care and patient empowerment and reducing the burden on our precious health human resources. However, we can't do this alone. To that end, we are delighted to enter this exclusive partnership with Cloud DX and scale their innovative technology, thoughtful service model, and excellent track record for delivering results to patients across the country."

Among its many awards, Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, a 2021 Edison Award winner, a Fast Company "World Changing Idea" finalist, and one of " Canada's Ten Most Prominent Telehealth Providers.

The shares are trading at $0.195. For more information, please visit the company's corporate website www.CloudDX.com, and the company's investor relation site ir.CloudDX.com/overview/default.aspx, contact Jay Bedard, Investor Relations, at 647-881-8418 or by email at jay.bedard@CloudDX.com.

About InvestmentPitch Media

Investmentpitch Media leverages the power of video, which together with its extensive distribution, positions a company's story ahead of the 1,000's of companies seeking awareness and funding from the financial community. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.

CONTACT:
InvestmentPitch Media
Barry Morgan, CFO
bmorgan@investmentpitch.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/106272

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

InspireMD Announces Promotion of Andrea Tommasoli to Chief Operating Officer

InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that it has promoted Andrea Tommasoli to Chief Operating Officer. Mr. Tommasoli formerly served as the Company's Senior Vice President of Global Sales & Marketing since joining InspireMD in November 2020.

"Andrea has been instrumental in expanding the footprint of CGuard EPS across our approved markets in the EU and, as we advance toward potential U.S. approval with our ongoing U.S. Investigational Device Exemption (IDE) clinical trial, and as our business requirements shift toward operational capacity to support our commercial growth, we believe his background and skill set make him an ideal candidate to assume the role of Chief Operating Officer of the Company at this important time," stated Marvin Slosman, Chief Executive Officer of InspireMD. "On behalf of the entire InspireMD team, I would like to congratulate Andrea on this promotion and look forward to his continued contributions."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

GeminiBio Appoints Industry Veteran Cory Stevenson as Executive Chairman

Gemini BioProducts Holding, Inc. ("GeminiBio" or the "Company"), a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Florida -based healthcare private equity firm, announced the appointment of Cory Stevenson as Executive Chairman of the Board of Directors.

(PRNewsfoto/BelHealth Investment Partners)

Mr. Stevenson joined the Board of GeminiBio in 2022 and has been working closely with the GeminiBio management team as they prepare to complete a three-phase buildout that addresses the long-term capacity needs in the biopharma and cell/gene therapy marketplace. Previously, Mr. Stevenson served as President of the BioProduction Division of Thermo Fisher Scientific (NYSE:TMO), a world leader in serving the biopharma sector, with annual revenue of more than $40 billion . During Cory's tenure, the BioProduction business grew from $200 million in revenues to over $2.5 billion annually.

Harold S. Blue , Managing Partner of BelHealth Investment Partners said, "We are fortunate to have Cory expand his role and guide our strategy at GeminiBio. Cory has been very helpful during the last year as a board member and I am excited that he will be taking a more active role. Also, given that Cory worked directly with GeminiBio's CEO, Brian Parker , while at Thermo Fisher, this was a natural fit."

Cory Stevenson , Executive Chairman of GeminiBio added, "I am delighted to expand my role at GeminiBio after working closely with Brian and the rest of the team since I joined the Board. With the completion of its 57,000-square-foot manufacturing facilities, GeminiBio is positioning itself as a vendor delivering much-needed critical solutions to the global biopharma industry. I am looking forward to this exciting next phase at GeminiBio."

About BelHealth Investment Partners

BelHealth Investment Partners, based in Fort Lauderdale, Florida , is a healthcare private equity firm focused on lower middle market companies. BelHealth has a unique combination of investing, executive management, and entrepreneurial experience. BelHealth acquires majority positions in entrepreneur-owned companies that it believes will benefit from its extensive operating and private equity investment expertise. For more information, visit www.belhealth.com .

About GeminiBio

Founded in 1985, GeminiBio serves the global biotechnology industry, from basic research to commercial production, with a focus on helping our customers accelerate the development of life enhancing biotherapeutics by streamlining and improving their cell culture and process liquid manufacturing workflows. The company's products are organized into two core verticals – Cell Culture Solutions and Process Liquid Solutions. Located in West Sacramento, California , GeminiBio has 57,000 square feet of cGMP manufacturing space that is segregated between animal origin free and animal component manufacturing. GeminiBio is an ISO 13485 certified, FDA registered Class 1 Medical Device Manufacturer, aligned with 21 CFR Part 820. For more information, visit www.geminibio.com .

Contact:
BelHealth: Inder Tallur , itallur@belhealth.com
GeminiBio: bparker@geminibio.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/geminibio-appoints-industry-veteran-cory-stevenson-as-executive-chairman-301774586.html

SOURCE BelHealth Investment Partners

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Notice of Knight Therapeutics' Fourth Quarter and Year End 2022 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2022 financial results on Thursday, March 23, 2023 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date : Thursday, March 23, 2023

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Janssen Announces Novel Dengue Antiviral Demonstrates Efficacy in Pre-Clinical Data Published in Nature

The antiviral is efficacious in non-human primates, and is safe and well-tolerated in humans

Findings support further clinical development for prevention and treatment of dengue, which impacts millions of people today and is poised to threaten many more due to climate change

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Medtronic receives CE Mark approval for Affera Mapping and Ablation System to treat atrial arrhythmias

First of its kind, all-in-one Sphere-9™ Catheter with pulsed field ablation, radiofrequency, and high density mapping integrated with intuitive mapping and navigation platform

Medtronic (NYSE:MDT) announced today that it has received CE ( Conformité Européenne ) Mark for the Affera™ Mapping and Ablation System, which includes the Sphere-9™ Catheter and the Affera™ Prism-1 Mapping Software. Together, the full system creates a new paradigm in electrophysiology through the unique integration of the Sphere-9 pulsed field ablation (PFA), radiofrequency (RF), and high density (HD) mapping catheter, which maps and ablates atrial arrhythmias (fast, abnormal heart rhythms) and provides real-time feedback through its intuitive mapping and navigation software. Atrial fibrillation (AFib) is the most common atrial arrhythmia, and nearly 60 million people are affected worldwide 1 and five million patients will be added every year by 2030 2 . Atrial arrhythmias, such as AFib, are associated with serious complications including heart failure, stroke and increased risk of death 3-6 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Medtronic named one of World's Most Ethical Companies

Recognition honors companies demonstrating business integrity through best-in-class ethics, compliance, and governance practices

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, has been recognized by Ethisphere, a leader in defining and advancing the standards of ethical business practices, as one of the 2023 World's Most Ethical Companies . In 2023, 135 honorees were recognized spanning 19 countries and 46 industries. Medtronic is one of only two honorees in the 'Healthcare Products' industry category.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×